Discontinuation of an Alpha-1 Blocker or 5-Alpha-Reductase Inhibitor after Combination Medical Treatment in Patients with Benign Prostatic Hyperplasia
作者： Yuan-Ming Liaw , Hann-Chorng Kuo
DOI: 10.6440/TZUCMJ.200604.0091
关键词:
摘要: Objective: To investigate changes in prostatic volume, uroflow measurements, and clinical benign hyperplasia (BPH) progression after withdrawal of an α-1 blocker or 5-α-reductase inhibitor (5ARI) patients receiving combination therapy with these agents. Materials Methods: A total 74 BPH were enrolled this 2-year trial medical treatment for BPH. The treated both tamsulosin finasteride 1 year, then randomly assigned to discontinue one the medications. uroflow, specific antigen, symptom score measured at baseline, end therapy, 12 months discontinuation medication. Therapeutic efficacies discontinuing medication compared between groups. Results: All parameters showed significant improvement Clinical was found during one-year follow-up 15 (35.7%) group (37.5%) group. remaining groups continued have good therapeutic results a single study. In discontinuation, volume antigen increased two year treatment. Patients had significantly higher than those without (42.5±17.2 v 32.0±12.2, p=0.05). resumed Conclusion: One following effects maintained 64.3% 62.5% patients, respectively.
sci-hub.st 参考文章(13)
Glenn J. Gormley, Elizabeth Stoner, Reginald C. Bruskewitz, Julianne Imperato-McGinley, Patrick C. Walsh, John D. McConnell, Gerald L. Andriole, Jack Geller, Bruce R. Bracken, Joyce S. Tenover, E. Darracott Vaughan, Frances Pappas, Alice Taylor, Bruce Binkowitz, Jennifer Ng, The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. The New England Journal of Medicine. ,vol. 327, pp. 1185- 1191 ,(1992) , 10.1056/NEJM199210223271701
J Barkin, M Guimaraes, G Jacobi, D Pushkar, S Taylor, OB van Vierssen Trip, Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor Dutasteride European Urology. ,vol. 44, pp. 461- 466 ,(2003) , 10.1016/S0302-2838(03)00367-1
Peter Boyle, A. Lawrence Gould, Claus G. Roehrborn, Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials* Urology. ,vol. 48, pp. 398- 405 ,(1996) , 10.1016/S0090-4295(96)00353-6
CLAUS G. ROEHRBORN, JOHN McCONNELL, JAIME BONILLA, SIDNEY ROSENBLATT, PERRY B. HUDSON, GHOLEM H. MALEK, PAUL F. SCHELLHAMMER, REGINALD BRUSKEWITZ, ALVIN M. MATSUMOTO, LLOYD H. HARRISON, HAROLD A. FUSELIER, PATRICK WALSH, JOHNNY ROY, GERALD ANDRIOLE, MARTIN RESNICK, JOANNE WALDSTREICHER, , SERUM PROSTATE SPECIFIC ANTIGEN IS A STRONG PREDICTOR OF FUTURE PROSTATE GROWTH IN MEN WITH BENIGN PROSTATIC HYPERPLASIA The Journal of Urology. ,vol. 163, pp. 13- 20 ,(2000) , 10.1016/S0022-5347(05)67962-1
Roger S Kirby, Claus Roehrborn, Peter Boyle, Georg Bartsch, Alain Jardin, Margaret M Cary, Michael Sweeney, Eric B Grossman, PREDICT Study Investigators, Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial Urology. ,vol. 61, pp. 119- 126 ,(2003) , 10.1016/S0090-4295(02)02114-3
P. Boyle, C. Roehrborn, I. Marks, R. Vela Navarrete, J.C. Nickel, The novel dual 5α-reductase inhibitor dutasteride is effective for the treatment and prevention of complications in men with a PV 30≤40 CC and 40 CC European Urology Supplements. ,vol. 2, pp. 160- ,(2003) , 10.1016/S1569-9056(03)80634-6
P Rigatti, , M Brausi, R M Scarpa, D Porru, H Schumacher, C A Rizzi, A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases. ,vol. 6, pp. 315- 323 ,(2003) , 10.1038/SJ.PCAN.4500680
HERBERT LEPOR, WILLIAM O. WILLIFORD, MICHAEL J. BARRY, CLAIR HAAKENSON, KAREN JONES, THE IMPACT OF MEDICAL THERAPY ON BOTHER DUE TO SYMPTOMS, QUALITY OF LIFE AND GLOBAL OUTCOME, AND FACTORS PREDICTING RESPONSE The Journal of Urology. ,vol. 160, pp. 1358- 1367 ,(1998) , 10.1016/S0022-5347(01)62536-9
John B. Anderson, Claus G. Roehrborn, Jack A. Schalken, Mark Emberton, The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. European Urology. ,vol. 39, pp. 390- 399 ,(2001) , 10.1159/000052475
Bob Djavan, Michael Marberger, A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction European Urology. ,vol. 36, pp. 1- 13 ,(1999) , 10.1159/000019919